期刊文献+

不同治疗方案治疗特发性膜性肾病82例疗效分析 被引量:1

原文传递
导出
摘要 目的比较特发性膜性肾病(IMN)各治疗方案的临床疗效,以探讨合理的治疗方案。方法分析82例IMN患者的临床资料和治疗方案,分成对症治疗组、单用激素组和糖皮质激素联合免疫抑制剂组(联合治疗组),比较各治疗方案的临床疗效。结果 (1)治疗前一般资料比较,仅对症治疗组24 h尿蛋白定量明显低于单用激素组和联合治疗组(P<0.05)。(2)对症治疗组、单用激素组和联合治疗组总缓解率分别为57.9%、42.9%和73.8%,对症治疗组分别与其余两组比较差异无统计学意义(P>0.05),但单用激素组比联合治疗组疗效差(P<0.05)。(3)将单用激素组和联合治疗组患者分成低危、中危和高危患者,对于中危和高危患者,联合治疗组的缓解率明显高于单用激素组(P<0.05)。(4)将所有患者分为缓解组和未缓解组,治疗前缓解组血肌酐明显低于未缓解组,而估算肾小球滤过率(eGFR)明显高于未缓解组(P<0.05)。结论糖皮质激素和免疫抑制剂联合治疗较单用激素治疗可明显提高IMN患者的疗效,尤其是对于中危和高危因素的患者,治疗前患者的肾功能是影响预后的重要因素。
出处 《苏州大学学报(医学版)》 CAS 北大核心 2011年第2期329-331,共3页 Suzhou University Journal of Medical Science
  • 相关文献

参考文献5

  • 1刘志红.膜性肾病的治疗[J].肾脏病与透析肾移植杂志,2009,18(4):353-355. 被引量:24
  • 2Cattran DC, Alexopoulos E, Ponticelli C, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations [ J ]. Kidney Int ,2007,72 ( 12 ) : 1429 - 1447.
  • 3陈薇,王德光.特发性膜性肾病的治疗进展[J].国外医学(老年医学分册),2009,30(4):185-189. 被引量:5
  • 4Schieppati A, Perna A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome [ J ]. Coehrane Database Syst Rev,2004,18 (4) :CD004293.
  • 5Branten A J, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide [ J ]. Am J Kidney Dis, 2007, 50(2) :248 -56.

二级参考文献30

  • 1Schieppati A, Mosconi L, Pema A et al. Prognosis of untreated patients with idiopathic membranous nephropathy, N EnglJ Med, 1993 ; 329 : 85 - 89.
  • 2Ponticelli C, Zuchelli P, Passefini Petal. A 10 -year fol- low - up of a randomized study with methylprednisolone and ehlorambucil in membranous nephropathy. Kidney Int, 1995 ; 48 : 1600 - 1604.
  • 3du Bur- Vereijken PW, Branten A J, Wetzels JF. Idiopathic membranous nephroathy : outlineand rationale of a treatment strategy. Am J KidneyDis, 2005; 46:1012 - 1029.
  • 4Muirhead N. Management of idiopathic membranous nephropathy : evidence - based recommendations. Kidney Int, 1999;S70: S47 - S50.
  • 5Cattran D. Management of membranous nephropathy: when and what for treatment. J AmSoc Nephrol, 2005; 16:1188 - 1194.
  • 6Cameron J S, HealyMJ, Adu D. The Medical Research Council trial of short - term high - dose alternate day predniselone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomenllonephritis Working Party. Q J Med, 1990; 74 (274) : 133 -156.
  • 7Shiiki H, Saito T, Nishitani Yet al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotie syndrome in Japan. Kidney Int, 2004 ; 65 (4) : 1400 -1407.
  • 8Kimura M, Toyoda M, Kobayashi K et al. A retrospective study on the efficacy of eortieosteroid- alone therapy in membranous nephropathy patients. Intern Med, 2007; 46 (19) : 1641 -1645.
  • 9Pontieelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Socnephrol, 1998 ; 9 : 444 - 450.
  • 10Pema A, Schieppati A, Zamora Jet al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis, 2004; 44 (3) : 385 -401.

共引文献27

同被引文献19

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部